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The Cosmetic/Drug Dilemma: FDA Regulation of 
Alpha-Hydroxy Acids 
LAURA A. HEYMANN. 
"Time doth transfix the flourish set on youth 
And delves the parallels in beauty's brow." 
- Shakespeare, Sonnet 60, I. 9-10 
"Old age is woman's hell." 
-Ninon de L'Enclos (1620-1705) 
I. INTRODUCTION 
In 1935, the New Yorker reported that 200 women visited Elizabeth Arden's New 
York salon each day to reap the benefits of the salon's "Vienna Youth Mask," "a 
device made ofpapier-mache and lined with tin foil," which was fitted to the face and 
connected to an electrical current to "replenish" the cells.1 There was, of course, no 
scientific evidence proving the mask's effectiveness. But this is not the case with 
alpha-hydroxy acids (AHAs), an ingredient in several dozen skin-cream formula-
tions. No product ingredient in recent memory has caused the reaction that AHAs 
have. Women's magazines, word of mouth, and aggressive marketing have spread the 
message that AHAs are the first skin-care ingredients that achieve lasting effects by 
exfoliating the top layer of skin, revealing "new" skin underneath. Soon after their 
appearance on the mass market in 1992, AHA products rapidly became a booming 
business. Sales of Avon's Anew, one of the first mass-marketed AHA products, totaled 
$70,000,000 in the product's first year on the market;2 in 1996 sales of AHA-based 
products reached a half-billion dollars a year.3 
In the midst of this furor, however, the question of the product's safety has, until 
recently, gone largely unanswered. Spurred by reports of adverse reactions to AHA-
based products, the Food and Drug Administration (FDA) began focusing a more 
critical eye on the industry early in 1995, believing the use of AHAs in cosmetics to 
represent "a significant departure from traditional cosmetic ingredients and prod-
ucts."4 Two subsequent clinical studies and a review by an industry panel have sug-
gested not only that the product does achieve its promised results but also that it is 
generally safe in low concentrations despite the possible increase in sun sensitivity. 
FDA currently is conducting its own review of the data and plans to issue its findings 
• Ms. Heymann currently is serving as a Clerk to the Hon. Patricia M. Wald, U.S. Court of Appeals for the 
D.C. Circuit. The views expressed in this article are solely those of the author. A previous version of this article 
won First Place in the 1997 H. Thomas Austem Memorial Writing Awards Competition sponsored by FDLI. 
1 MARGARET AllEN, SELLING DREAMs: INSIDE mE BEAUTY BusiNESs 33 (1981 ). 
2 Patricia McLaughlin, About Face, Plm.ADELPHIA INQUIRER, Mar. 7, 1993, at 31. The product's success 
inspired manufacturers to introduce more than 50 AHA products to the market in 1993. Susan Sargisson, The 
AHA Phenomenon, DRUG & CosM.INnus., Jan. I, 1994, at 24. 
3 Lauren Neergaard, FDA to Study Wrinkle Cream, Effect of Sensitivity to Sun, COURIER -J. (Louisville, 
KY), Dec. 22, 1996, at 14A. 
4 Letter from John Bailey, Dir., Off. of Cosmetics and Colors, FDA, to Alan Andersen, Sci. Coordinator 
and Dir., Cosmetic Ingredient Review Expert Panel, CTF A (Nov. 30, 1995), quoted in F-D-C REP. ("The Rose 
Sheet"), Dec. 11, 1995, at I, 3. 
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before the end of 1997. The agency also plans to meet with the cosmetics industry to 
discuss an appropriate response. s 
One of the primary, and indeed threshold, questions facing FDA in this review is 
whether products containing AHAs are to be considered cosmetics or drugs under the 
Federal Food, Drug, and Cosmetic Act of 1938 (FDCA),6 the statutory basis for the 
agency's regulatory power. Under most interpretations of the FDCA with regard to 
cosmetics, the answer to this question would be rooted not in the chemical composi-
tion or physiological effect of AHAs but rather in how the manufacturer has posi-
tioned the product and the promises made as to its effects.7 The cosmetic/drug distinc-
tion has considerable implications for the cosmetics industry because of the difference 
in regulation between cosmetics and drugs, most notably the lack of any requirement 
of premarket review for cosmetic products. A decision that AHAs are to be regulated 
as drugs could force manufacturers to pull available products from the market and 
submit extensive tests as to the products' safety and effectiveness for FDA approval, 
clearly an undesirable result for the industry. But a decision that the products are to be 
treated as cosmetics means that any regulation of their safety comes completely ex 
post in the form of product liability suits8 or FDA seizure proceedings, which involve 
considerable government resources. 
This paper will review the history of the FDCA, the current state of the law, and 
the likely resolution ofthis issue as the FDCA now stands. It ultimately concludes that 
perhaps the biggest obstacle to the resolution of this and similar issues arising from 
the cosmetic/drug distinction is the lack of a statutory definition that would encom-
pass cosmetic products that have drug-like effects. This paper suggests that, in light of 
industry developments, congressional reexamination of the FDCA is in order. 
II. BACKGROUND 
A. Alpha-Hydroxy Acids 
AHAs have been used for many years to adjust pH levels in cosmetic products, but 
it is only recently that they have been touted as the elixir of youth.9 The term AHA 
comprises a group of organic carboxylic acids in which a hydroxy group is at the 
alpha position, including glycolic, lactic, citric, malic, mandelic, and tartaric acids.10 
Each of these acids has a natural derivation but now also is produced synthetically for 
use in creams and lotions. 11 Products sold to the mass market generally contain less 
than ten percent AHA; products sold for use in salons typically contain twenty percent 
1 Neergaard, supra note 3, at 14A. 
6 Pub. L. No. 75-717, § 201(g), (h), 52 Stat. 1040, 1041 (codified as amended 21 U.S.C. § 321(g), (h) 
(1994)). 
7 This interpretation is now open to question after a recent federal court ruling that upheld the FDA's power 
to regulate tobacco. See infra text accompanying notes 82-87. 
1 Of course, the possibility of suit is an incentive for manufacturers to ensure the safety of their products 
before marketing them. See infra text accompanying notes 123-24. 
o The first patent for AHAs was filed in 1976 by Drs. Eugene Van Scott and Ruey J. Yu, who are credited 
with discovery of the potential of AHAs. See Sargisson, supra note 2, at 24; Eugene J. Van Scott & Ruey J. Yu, 
Alpha-Hydroxy Acids: Procedures for Use in Clinical Practice, 43 CUTIS 222 ( 1989). 
10 Zos DIANA DRAHOS, CosMIITJcs IN DllRMATOLOOY 241 (2d ed. 1995). 
11 Jd. Glycolic acid is derived from sugar cane, lactic acid is derived from fermented milk, citric acid is 
found in citrus fruits, malic acid is found in unripened apples, mandelic acid is an extract ofbitter almonds, and 
tartaric acid is found in fermented grapes. Jd. 
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to forty percent AHA; and products sold for medical use can contain as much as 
seventy percent AHA.12 
Although the acids have been isolated comparatively recently, women have used 
substances containing AHAs as a facial preparation for centuries. Women in ancient 
Rome, for example, would use the sludge from wine barrels as a facial mask, and 
Cleopatra is said to have bathed in sour milk (a source of lactic acid) as a beauty 
treatment. 13 The Duchess of Alba applied orange pulp to her face, and Queen Eliza-
beth of Hungary, in the nineteenth century, would create beauty preparations from 
lemons and wine. 14 Mass marketing of AHAs also predated the twentieth century -
Guerlain, the cosmetics manufacturer, marketed "cosmetic vinegars" based on fruit 
acids in 1830. 15 
Researchers have not determined definitively how AHAs work, but it is believed 
that they have two primary effects on the skin. First, the acids loosen the bonds in the 
stratum corneum (within the epidermis) that hold dead skin cells together, which 
encourages a faster sloughing process and the production of new skin cells. Second, 
the acids are believed to thicken underlying layers of the skin and increase the amount 
of hyaluronic acid, a gelatinous substance that holds cells together. 16 It is still unclear, 
however, exactly what effect AHAs have on deeper levels of the skin, a question that 
may become crucial to the issue of FDA regulation. 
Despite its extensive lineage, the safety of AHAs, particularly at higher concen-
trations, remains uncertain. One concern is that absent regulation, manufacturers will 
attempt a race to the top, increasing concentration of the acid in their products to 
achieve a more drastic effect. 17 But as the AHA concentration increases, so does the 
chance of adverse side effects, particularly a burning of the skin. In 1994, the FDA 
received more than thirty-five reports of adverse reactions to AHAs, which repre-
sented forty-four percent of such reports concerning skin-care products for the year.18 
These concerns, coupled with the recent increase in the number of products marketed 
that contain AHAs, 19 have spurred several clinical studies. One such study, conducted 
jointly by researchers from Boston's Massachusetts General Hospital and Beth Israel 
Hospital, concluded that AHAs had "modest but real benefits" in women with mild to 
moderate photoaging (sun damage).20 (The researchers were careful to distinguish 
12 Anita Shaw, The News in Skin Care, SoAP-CosM.-CHEM. SPECIALTIES, Oct. I, 1996, at 72. 
13 Maria Liberati, Alpha & Beta Hydroxy Acids: The Skin-Care Revolution, BETTER NuTRITION, Apr. 
1996, at 70. 
l4Jd. 
•s Shelley M. Colwell, AHAs: The Reigning Ingredient, SoAP-CosM.-CHEM. SPECIALTIES, Feb. I, 1996, at 
30 (citing Dana Glazer, Dir., Pub. Relations, Guerlain). 
16 Susan Brink, The Dewrinkling of America, Alpha Hydroxy Acids in Pricey Creams Are the Latest 
Antiaging Elixir, U.S. News & WoRLD REP., Jun. 6, 1994, at 79; Bernard Idson, Retinoids and AHAs, DRUG & 
CosM. INous., May I, 1995, at 24. 
17 See, e.g., Colwell, supra note 15, at 30 (quoting Alex Znaiden, Dir., Global Skin Innovation Center, 
Chesebrough-Pond 's) ("If you have delivered the concentration, that's going to keep your customer with you."). 
18 Alpha Hydroxy Acids (AHAs), U.S. Food & Drug Admin., Ctr. for Food Safety & Applied Nutrition, 
Office of Cosmetics Fact Sheet (May 3, 1995). Based on the 97 complaints received by the agency since 1989, 
and on the agency's assumption that one report to the agency equals approximately 50 to I 00 ·reports received by 
manufacturers, FDA estimated that cosmetic companies had received about I 0,000 reports of adverse reactions 
to AHAs. F-D-C REP. ("The Rose Sheet"), Mar. 4, 1996, at 5. Industry representatives have questioned this 
finding, noting that the recent publicity given to AHAs likely encouraged a higher rate of adverse reaction 
reports. See F-D-C REP. ("The Rose Sheet"), Mar. II, 1996, at 1-3. 
19 FDA's available data, which is reported voluntarily by the industry, indicated that glycolic acid was used 
in 90 products in 1996. F-D-C REP. ("The Rose Sheet"), Dec. 23. 1996, at 1-3. 
20 Matthew J. Stiller et al., Topical8% Glycolic Acid and 8% L-Lactic Acid Creams for the Treatment of 
Photodamaged Skin, 132 ARCHIVES OF DERMATOLOGY 631, 632 (1996). The double-blind, vehicle-controlled 
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photoaging, or "extrinsic aging," upon which AHAs could have an effect, from intrin-
sic aging- resulting from a genetic decline in physiological functions- upon which 
AHAs have no effect.)21 
A second study, published three months later, concluded that a five percent lactic 
acid formula caused a significant increase in superficial skin firmness; a twelve per-
cent formula also caused increases in integral skin firmness.22 The acid also caused an 
increase in epidermal thickness (with an increase in dermal thickness at the higher 
concentration), as well as improvement in the appearance of lines and wrinkles.23 The 
study also concluded that the skin eventually would become resistant to AHA at the 
five percent concentration such that no additional benefits would become apparent.24 
Two more recent studies have proven to be of particular interest to FDA. A study 
conducted by FDA's Office of Cosmetics and Colors in December 1996 concluded that 
although AHAs do not affect the skin's penetrability, they do "drastically alter[]" the 
structure of the skin, inducing as much as a four-fold increase in the thickness of the 
epidermis (the top layer of the skin).25 In the spring of 1997, the Cosmetic Ingredient 
Review (CIR), an independent review panel established by the Cosmetic, Toiletry, and 
Fragrance Association (CTFA), completed its study of the safety of AHAs, concluding 
that AHAs are safe for use in retail products at concentrations of ten percent or less in 
a finished product formula with a pH of 3.5. The CIR also took note of the increased 
sun sensitivity caused by the AHA lotions and concluded that products either should 
be formulated to take this into account or should carry a recommendation that con-
sumers wear sunscreen. 26 
Several industry journals have pointed to the weakness of this study, noting that 
successful implementation relies heavily on self-regulation and that the "lucrative 
market" for AHA-based products may have influenced the result.27 FDA is conducting 
its own study (possibly with these concerns in mind) and is considering regulatory 
options, particularly in light of the agency's history of regulating anti-aging products. 
B. FDA Regulation of Anti-Aging Products 
FDA historically has looked at "wrinkle creams" and other anti-aging products 
with a somewhat skeptical eye. The genesis of the most recent surveillance was in 
1985, when FDA Commissioner Frank E. Young, in a speech to the CTFA, warned 
manufacturers of skin-care products to tone down their extreme claims or risk a regu-
study was funded in part by Unilever, parent company ofChesebrough-Pond's, the manufacturer of the products 
used in the study. Unilever was not, however, involved in the study's design or conduct. Doug Levy, Beauty: 
Age-DefYing Creams Really Work but FDA Stays Cautious, DERMATOLOGY NEWs, Jun. 15, 1996, at Cl. 
21 Stiller et al., supra note 20, at 635. 
22 Walter P. Smith, Epidermal and Dermal Effects ofTopical Lactic Acid, 35 J. AMER. AcAD. OF DERMATOL-
OGY 388, 389 (1996). 
2lJd. 
24 ld. at 390. 
25 F-D-C REP. ("The Rose Sheet"), Dec. 23, 1996, at 5. This study was conducted on hairless guinea pigs 
and thus has been criticized as an inappropriate model for human skin, which has a different absorption rate. See 
id. at 6 (describing findings ofNonnan Weiner, Ph.D.). 
26 Anita Shaw, An AHA Update, SoAP-COsM.-CHEM. SPECIALTIES, Mar. I, 1997, at 30. See also Statement of 
the Cosmetic, Toiletry, and Fragrance Association on the Cosmetic Ingredient Review, Upholding the Safety of 
Alpha-Hydroxy Acids (Dec. 17, 1996). 
27 Sensitive Feelings, CosM. INSIDERS REP., Feb. 10, 1997; see also Not Likely!, DRUG & CosM. INDus., Feb. 
1, 1997, at 20. These editorials attacked the preliminary version of the CIR study; the panel reached the same 
conclusions in its final report. 
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latory response. 28 In 1987, DanielL. Michels, Director of the Office of Compliance for 
FDA's Center for Drugs and Biologics, sent warning letters to more than twenty cos-
metic manufacturers and distributors regarding what the agency believed to be thera-
peutic claims about certain anti-aging or anti-wrinkle creams.29 Michels informed the 
companies that on the basis of these claims, the products were unapproved new drugs 
that would be subject to regulation if the companies failed to act.30 The companies, in 
response, called for a new perspective on products that were the result of advances in 
cosmetic technologyY Another round of letters from the agency followed, stating: 
[W]e consider a claim that a product will affect the body in some physiologi-
cal way to be a drug claim, even if the claim is that the effect is only tempo-
rary .... Therefore, we consider most of the anti-aging and skin physiology 
claims ... to be drug claims .... [W]e would consider a product that claims 
to improve or to maintain temporarily the appearance or the feel of the skin 
to be a cosmetic. For example, a product that claims to moisturize or soften 
the skin is a cosmetic.32 
FDA eventually gave the companies a deadline of April 24, 1988, to change their 
claims or face the possibility of regulatory action; most complied.33 
In 1992, FDA targeted Global Esthetics, the manufacturer of a product called 
"PeelAway," which used high levels of AHAs to cause skin peeling. 34 The manufac-
turer claimed the product would remove wrinkles, blemishes, and blotches; FDA re-
ceived four reports of skin burns in consumers of the product. In a warning letter sent 
to the manufacturer, FDA stated that it considered PeelAway to be an unapproved new 
drug and that the product was misbranded and presented a "significant health haz-
ard. "35 
As of this writing, FDA has taken no action against manufacturers of AHA-based 
products, although it has raised concerns regarding their safety.36 Because any power 
FDA has in this regard is the result of statutory grant, further consideration of this 
issue requires a brief look at the FDCA. 
28 Emalee G. Murphy, Cosmeceuticals- The Regulatory Environment or the Cosmetic Wars and Other 
Phenomena, 44 FooD DRUG CosM. L.J. 41,41 (1989). 
29 See Estee Lauder, Inc. v. U.S. Food & Drug Admin., 727 F. Supp. 1 (D.D.C. 1989), in which the District 
Court for the District of Columbia rejected a challenge by the Estee Lauder company to the regulatory authority 
of FDA over seven of its skin creams. The company had claimed in advertisements that its "Night Repair Cellu-
lar Recovery Complex" would "accelerate the natural repair of cells" and that the cream had "changed the 
science of skin care to skin repair." The company also had claimed that other products would "restructure and 
repair" the skin and "work inside cell layers to counteract aging forces." !d. at 3 n.1. Avon received a warning 
letter regarding its product BioAdvance, for which it had claimed, "Actually helps reverse many signs of facial 
aging in just 6 weeks .... " F-D-C REP. ("The Rose Sheet"), Mar. 18, 1996, at 12, 14. 
30 Murphy, supra note 28, at 43-44. 
31 Id. at44. 
32 /d. at 44-45 (quoting cosmetic regulatory letters from John M. Taylor, Assoc. Comm'r for Reg. Affs., to 
cosmetic skin care companies (Nov. 19, 1987)). 
33 Id. at 45; Thomas J. Donegan, Fifty Years of Cosmetic Safety: A Government and Industry Partner-
ship, 50 FooD & DRUG L.J. 151, 158 (1995). 
34 Skin Peelers, HHS News, U.S. Dept. ofHea1th & Human Servs., Food & Drug Admin., P92-13 (May 
21, 1992). 
35 /d. 
36 
"Little is known about the overall safety of AHAs when they are used as chemical exfoliants because this 
is a relatively new application." AHAs, Office of Cosmetics Fact Sheet, supra note 18. John Bailey, Director of 
the agency's Office of Cosmetics and Colors, has suggested that regulation of AHAs is among the agency's 
current priorities. See Countercurrents, CosM. INSIDERS' REP., Mar. 24, 1997. 
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C. The Federal Food, Drug, and Cosmetic Act of 1938 
1. Legislative History 
VoL. 52 
FDA's power to regulate cosmetic products appeared for the first time in the FDCA. 
Government regulation of cosmetics had not been included in the 1906 Food and 
Drug Act,37 a lacuna that was noted by an agency official in 1917: "While the accom-
plishments of the Food and Drug Act have been considerable, it must be admitted that 
it has its serious limitations. Especially conspicuous ones are ... the limitations placed 
upon the term 'drug' by definition which render it difficult to control injurious cos-
metics ... . "38 Senator Copeland of New York took up the challenge in 1933, moti-
vated by reports from the agency of cosmetic injury from such products as "Koremlu 
Cream," a depilatory containing thallium acetate, a highly poisonous chemical. The 
product, as stated by FDA in its annual report in 1933, had been represented as "en-
tirely harmless and actually beneficial to the skin," and its widespread popularity had 
caused "many cases of severe injury to users before the manufacturer was forced into 
bankruptcy by accumulation of damage suits. The Federal Government, lacking legal 
authority to control cosmetics, was unable to give the consumer the protection which 
should have been afforded."39 Copeland thus introduced S. 1994, the first of several 
versions of the Act, on June 6, 1933. The Senate's concern over cosmetic safety was 
manifest in section 5 of the bill, which prohibited adulterated cosmetics. Under the 
proposed legislation, a cosmetic would be deemed adulterated if it was or could be 
"injurious" to the user under the usual or prescribed conditions of use, or if it con-
tained any "poisonous or deleterious ingredient" limited or prohibited by agency regu-
lation.40 The breadth of S. 1994, however, "met with violent opposition from every 
section of the country,"41 and its substitute, S. 2000, changed the first part of section 5 
to define an adulterated cosmetic as one that "bears or contains any poisonous or 
deleterious substance" that might render it injurious to the user under the usual or 
prescribed conditions of use.42 The change, which substantially was maintained in 
later versions of the bill, thus focused FDA regulation on the composition of the cos-
metic as the source of injury. 
Another change in the legislation as it passed through its various versions oc-
curred in the definition of the term "drug." In the original Senate bill, as in the FDCA 
as it now reads, food was excluded from the last portion of the definition of "drug": 
"all substances, preparations, and devices (other than food) intended to affect the 
structure of any function of the body." By the time the bill reached the House Commit-
37 Pub. L. No. 59-384, 34 Stat. 768 (1906). 
38 Annual Report of the Chief of the Bureau of Chemistry, Food & Drug Admin. (1917), reprinted in 
FEDERAL FooD. DRuG AND CosMETIC Acr: A STATEMENT oF ITs LEGISLATIVE REcoRD 24-25 (Charles Wesley Dunn 
ed. 1938) [hereinafter LEGISLATIVE REcoRD). 
39 Annual Report of the Food & Drug Admin. for Fiscal Year Ending June 30, 1933, reprinted in LEGISLA-
TIVE REcoRD, supra note 38, at 26. The dangers ofKoremlu Cream also had been well documented in ARTHUR 
KALLEn & F.J. ScHLINK, I 00,000,000 GuiNEA PIGS 80-88 ( 1933). 
40 S. 1994, 73d Cong. § 5 ( 1933), reprinted in LEGISLATIVE RECORD, supra note 38, at 39. 
41 As a Senate report on yet another version of the bill noted, the bill was revised "for the purpose of 
allaying the apprehensions ofhonest manufacturers without sacrificing the essential requirements for consumer 
protection." S. REP. No. 361, 74th Cong. (1935), reprinted in LEGISLATIVE REcoRD, supra note 38, at 238. 
42 LEGISLATIVE REcoRD, supra note 38, at 54. "jThe statute] would not prevent the marketing of a face 
powder or cream or any other cosmetic which did not contain poisonous or deleterious ingredients, even though 
such cosmetics might contain ingredients to which a certain class of unfortunate people are allergic." S. REP. No. 
361, 74th Con g. ( 1935), quoted in PETER BAKTON Hun & RicHARD A. MERRILL, FooD AND DRUG LAw: CASES AND 
MATERIALS 815 (2d ed. 1991). 
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tee on Interstate and Foreign Commerce on May 31, 1935, both food and cosmetics 
were excluded from the definition.43 This version of the bill died in the House, how-
ever, and when the bill was reintroduced asS. 5 in the Senate on January 6, 1937, the 
cosmetics exception was no longer present.44 As a result, the definitions of"drug" and 
"cosmetic" are not mutually exclusive, and a product that fits both definitions must 
comply with both sets of regulations. 45 
2. The Regulation of Cosmetics and Drugs Under the FDCA 
The regulation of cosmetics under the FDCA differs from the regulation of drugs 
in one significant respect: Cosmetic manufacturers are exempt from premarket review 
of their products. This means that a potentially dangerous cosmetic usually is discov-
ered only after it has reached the market and caused conspicuous harm to a consumer. 
Cosmetic regulation is delineated in sections 361 to 363 of title 21 of the United 
States Code, which, in conjunction with section 331, prohibit the adulteration46 or 
misbranding47 of any cosmetic in interstate commerce. Thus, a cosmetic product can 
be unlawful either as a result of its substance or as a result of its labeling. A cosmetic 
product is unlawful if it contains a "poisonous or deleterious substance which may 
render it injurious" pursuant to customary use;48 if it contains a "filthy, putrid, or 
decomposed substance";49 or if it has been manufactured or packaged under unsani-
tary conditions. 50 A cosmetic also may be found unlawful if its label or container is 
false or misleading51 or if it fails to bear required information. 52 The FDCA thus gives 
FDA the authority to regulate products on the market that are found to be particularly 
harmful or for which misleading claims have been made. But because the FDCA does 
not require cosmetic manufacturers to submit any information to the agency, regula-
tion must be conducted entirely on the basis of information voluntarily supplied by 
manufacturers53 or on a postmarket basis in response to consumer complaints or other 
alerting mechanisms. 
Drug regulation, by contrast, is considerably more extensive, with much of the 
statutory subchapter devoted to safety. 54 As with cosmetics, the adulteration of drugs 
is prohibited, although the FDCA further provides that a drug may be considered 
adulterated if it is not manufactured in accord with "current good manufacturing prac-
tices" to ensure safety, quality, and purity. 55 A drug, like a cosmetic, is unlawful if it is 
43 LEGISLATIVE RECORD, supra note 38, at 297. 
44 /d. at 638. No reason appears in the legislative history for the exception's appearance or subsequent 
disappearance. 
45 FOOD & DRUG ADMIJII., CENTER FOR FOOD SAFElY & APPLIED NUTRITION, COSMETICS HANDBOOK { 1992). 
46 21 U.S.C. § 361 {FDCA § 601). 
47 !d. § 362 (FDCA § 602). 
48Jd. 
49 /d. § 36I{b) {FDCA § 60I{b)). 
so !d. § 36I(c) (FDCA § 60I(c)). 
51/d. § 362{a), (d) (FDCA § 602(a), (d)). 
52 /d. § 362(b), (c) (FDCA § 602(b), {c)). 
'
3 The voluntary regulations are codified at 21 C.F.R. pts. 710,720,730 {1996). 
54 Many of the burdens of approval can be alleviated if the drug conforms to an already-existing over-the-
counter (OTC) drug monograph, which provides a set of regulatory standards for various OTC drugs. Premarket 
approval is not required for drugs that conform to these standards. William E. Gilbertson, The Impact of the 
FDA s Over-the-Counter Drug Review Program on the Regulation of Cosmetics, in THE CosMETIC INDUSTRY 
7 I, 79-80 (Norman F. Estrin ed. 1984). 
"21 U.S.C. § 35l(a)(2)(8) (FDCA § 50l(a)(2){8)). 
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misbranded, that is, if its label is false, misleading, fails to give adequate directions 
for use, or otherwise does not conform to the law,56 or if the drug is dangerous to 
health when used as recommended. 57 Here, however, the similarity to cosmetics regu-
lation ends. The FDCA further provides that all drug manufacturers must register 
with the Secretary of the Department of Health and Human Services (DHHS) and 
provide a list of all drugs manufactured. 58 Furthermore, no new drug may be placed on 
the market without application to and approval from the agency. The application must 
contain full reports of research conducted as to the safety and efficacy of the drug; a 
complete list of the drug's ingredients and description of its manufacturing process; 
and a sample of the proposed labeling for the drug. 59 Once the drug has been ap-
proved, the manufacturer must submit to the agency any information regarding clini-
cal trials or any other information that suggests that the drug is a hazard to public 
health,60 and the agency may revoke its approval upon review of this information.61 
In sum, the FDCA provides for considerable premarket review of any new drug, 
particularly with respect to the safety and efficacy of the drug. No such review takes 
place for new cosmetics, nor are cosmetic manufacturers required to register with 
FDA, a situation that has concerned Congress enough to initiate hearings and legisla-
tion,62 but not enough to amend the FDCA.63 
Of course, how a product is to be regulated depends entirely on how it is defined. 
The FDCA defines "cosmetic" as 
( 1) articles intended to be rubbed, poured, sprinkled, or sprayed on, intro-
duced into, or otherwise applied to the human body or any part thereof for 
cleansing, beautifying, promoting attractiveness, or altering the appearance, 
and (2) articles intended for use as a component of any such articles; except 
that such term shall not include soap64 
and "drug" as "(B) articles intended for use in the diagnosis, cure, mitigation, treat-
ment, or prevention of disease in man or other animals; and (C) articles (other than 
food) intended to affect the structure or any function of the body of man or other 
animals . ... "65 The Supreme Court has tended to read this definition expansively 
and thus not confined itselfto the strict medical definition of the word "drug."66 "Con-
S6 Jd. § 352(a), (b), (c), (t) (FDCA § 502(a), (b), (c), (t)). 
Sl /d. § 352(j) (FDCA § 502 (j)). 
Si /d. § 360 (FDCA § 51 0). 
59 /d.§ 355(b) (FDCA § SOS(b)). Of course, the procedure is considerably more complex than the brief 
summary offered here. 
60 /d. § 355(k) (FDCA § SOS(k)). 
61 /d.§ 355(e) (FDCA §50S( e)). 
62 See Jacqueline A. Greff, Regulation of Cosmetics That Are Also Drugs, 5! Fooo & DRuo L.J. 243, 244 
n.l4 (1996) (citing, e.g., H.R. 2244, 83d Cong. (1953); H.R. 4476, 84th Cong. {1955); H.R. 4015, 85th Cong. 
(1957); H.R. 4431, 85th Cong. (1957); H.R. 9153, 85th Cong. (1957); H.R. 1360, 86th Cong. {1959); H.R. 
5661, 86th Cong. (1959); H.R. 1235, 87th Cong. (1961); H.R. 11,582, 87th Cong. (1962); H.R. 1235, 88th 
Cong. (1963); H.R. 5777, 88th Cong. (1963); H.R. 6788, 88th Cong. (1963); H.R. 8418, 88th Cong. (1963); 
H.R. 1235, 89th Cong., (1965); H.R. 1235, 90th Cong. (1967); H.R. 4486, 90th Cong. (1967)). 
63 
"In my view, these regulatory gaps raise serious questions about the Food and Drug Administration's 
ability to effectively oversee the cosmetics industry in this country." Potential Health Hazards of Cosmetic 
Products: Hearings Before the Subcomm. on Reg. and Bus. Opportunities of the House Comm. on Small 
Bus., 100th Cong. 2 (1989) [hereinafter Hearings] (statement ofRep. Wyden, Comm. Chair). 
64 21 U.S.C. § 321(I)(FDCA § 201(i)). 
61 Jd. § 32l(g)(l) (FCDA § 201(g)(l)). 
66 United States v. An Article of Drug ... Bacto-Unidisk ... , 394 U.S. 784, 793 (1969). 
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gress fully intended," the Court noted in 1969, "that the Act's coverage be broad as its 
literal language indicates - and equally clearly, broader than any strict medical defi-
nition might otherwise allow. "67 This creates considerable problems for manufactur-
ers of many cosmetic products because almost any cosmetic can be said to have some 
effect on the structure of the body, however minute. 68 In reality, the practical distinc-
tion has come to be that a cosmetic is a substance that engenders a temporary, super-
ficial effect, linked closely to one's appearance, while a drug is a substance that causes 
a more permanent, structural change in one's health. There is no requirement, how-
ever, that a product's effects take place as a result of chemical or metabolic action for 
the product to be considered a drug - the agency interprets the statutory definition of 
"drug" simply as "a chemical or a combination of chemicals in liquid, paste, powder, 
or other drug dosage form that is ingested, injected, or instilled into body orifices, or 
rubbed or poured onto the body in order to achieve its intended medical purpose."69 To 
date, FDA has declined to establish guidelines that would elucidate the cosmetic/drug 
distinction, stating that each claim has to be examined in context. 70 
The key to both definitions, however, is the word "intended" - a product can be 
classified as a drug or as a cosmetic only if it is intended to be used as one. Thus, both 
definitions are driven not by the chemical composition of the product but rather by the 
objective intenf1 of the manufacturer in marketing the product- until recently, whether 
the manufacturer promoted the product as having therapeutic or merely superficial 
effects. 72 As the Second Circuit noted in 1969, "Regardless of the actual physical 
effect of a product, it will be deemed a drug for purposes of the Act where the labeling 
and promotional claims show intended uses that bring it within the drug definition.''73 
This focus has resulted in a rather untenable system, in that the status of a product 
may change according to the whims of the manufacturer, depending on the advertis-
ing claims the manufacturer has promulgated, the label, promotional material, and 
"any other relevant source."74 A savvy manufacturer could keep its product from ex-
tensive regulation and premarket testing, regardless of the product's safety, merely by 
67 I d. at 798. As a result, the Court held that a disc used by physicians to determine the correct antibiotic to 
administer to patients fell within the Act's definition of"drug." /d. at 799-800. 
68 See Compounder's Corner, DRuG & CosM. INDus., Mar. I, 1997, at 64 (noting belief that the FDCA's 
definition of cosmetics is a ''biological oxymoron"). 
69 Reclassification ofLacrisert as an Approved New Drug, 47 Fed. Reg. 46,139,46,140 (1982). Note, 
however, that the statutory definition of"device," at 21 U .S.C. § 321 (h), is almost identical to that of drug save 
that the definition of"device" contains the restriction "which does not achieve its primary intended purposes 
through chemical action within or on the body of man or other animals and which is not dependent upon being 
metabolized for the achievement of its primary intended purposes," suggesting that "drugs," by contrast, do act 
in this manner. 
70 Donegan, supra note 33, at 158. 
71 See 21 C.F.R. §§ 201.128, 801.4 ("The words 'intended uses' ... refer to the objective intent of the 
persons legally responsible for the labeling of drugs."). 
72 See Donegan, supra note 33, at 152 (noting that labeling or advertising claims are "usually determina-
tive" of product classification). 
73 United States v. An Article ... Consisting of216 Individually Cartoned Bottles, More or Less, of an 
Article Labeled in Part: Sudden Change, 409 F.2d 734, 739 (2d Cir. 1969). This interpretation has been sup-
ported by the legislative history of the Act. SeeS. REP. No. 361, 74th Cong., 1st Sess. (1935), reprinted in 
LEGISLATIVE REcoRD, supra note 38, at 240: "The use to which the product is to be put will determine the category 
into which it will fall .... The manufacturer of the article, through his representations in connection with its sale, 
can determine the use to which the article is to be put." A federal district court has rejected reliance on this 
statement, however, noting that "Congress' use of'can' rather than 'will' arguably shows that Congress did not 
intend for manufacturer representations to provide the only evidence of intended use." Coyne Beahm, Inc. v. U.S. 
Food & Drug Admin., 966 F. Supp. 1374, 1389 (M.D.N.C. 1997). 
74 See Sudden Change, 409 F.2d at 739. 
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couching any advertising claims in vague, unverifiable language.75 Moreover, whether 
a product actually has an effect on a structure or function of the body would be irrel-
evant: If the manufacturer claims it does, it is considered a drug; if it does not, it is 
considered a cosmetic. A dangerous chemical for which only cosmetic claims were 
made might avoid premarket regulation, whereas a claim that a product consisting 
wholly ofwater76 would "plump up skin cells" would cause the product to be regulated 
as a drug.77 
The incongruity of such a system of regulation is best illustrated by three cases in 
the late 1960s and early 1970s in which com1s grappled with the cosmetic/drug dis-
tinction in considering whether a "wrinkle remover" should be considered a cosmetic 
or a drug.78 Although marketed by a different company and under a different name in 
each case, the product was identical - a combination of bovine albumin and water 
that, when applied to the face, formed a film that temporarily smoothed out wrinkles. 
Two of the courts found the product to be a drug; one found it to be a cosmetic. The 
Second Circuit held that because the manufacturer claimed that the product would 
give a "face lift without surgery" and would "lift out puffs," it should be deemed a 
drug.79 Similarly, the Third Circuit held that because the manufacturer included such 
phrases in its advertising as "super-active," "amazing protein lotion," and "tighten-
ing the skin," it implied that the product was therapeutic rather than cosmetic in 
nature and thus should be regulated as a drug. 80 In contrast, a federal district court in 
Maryland held the product to be a cosmetic, finding that the claims made for the 
product under consideration (which included the claim that the product was a "pure 
protein" that caused an "astringent sensation") did not approach the level of the claims 
made for the other two products.81 
This relatively settled equation of intent and product claims has been called into 
question by a federal district court ruling in North Carolina that upheld FDA's power 
to regulate tobaccoY The industry had claimed that a product's intended use could be 
established only by the claims of manufacturers and that, because cigarette manufac-
turers had made no advertising claims regarding nicotine's effect on the structure or 
function of the body, nicotine could not be regulated as a drug.83 The court rejected 
this position, holding that the "plain meaning" of "intend" in the FDCA "does not 
7s Manufacturers are well aware of this power. See, for example, Michele Picozzi, Discovering 
Cosmeceuticals (visited Jan. 14, 1997) <http://www.newhope.com/tradezonellibrarylhbdpc/pc3 .html>, in which 
Rebecca James Gadberry, an industry consultant, suggests that manufactures and retailers of cosmeceuticals "be 
careful about making claims" and "avoid phrases that could be construed as drug-like claims." See also 
Compounders Corner, supra note 68, at 64 ("In practical terms, representation that the product penetrates the 
skin is an instant red flag to the FDA, denoting the possibility of systemic (drug) effects."). 
76 See, e.g., Bradley v. United States, 264 F. 79 (5th Cir. 1920) (mineral water that contained therapeutic 
claims on label classified as drug under 1906 Food and Drugs Act). 
77 Or, as one commentator put it, "You could make a very nice eyeshadow that cures cancer [and] as long 
as you said this was an eyeshadow and you didn't say that it cured cancer, you could sell it as a cosmetic." F-D-
C REP. ("The Rose Sheet"), Mar. 18, 1996, at II (quoting Gerald McEwen, Vice Pres. for Sci., CTFA). 
78 Sudden Change, 409 F.2d at 734; United States v. Article Consisting of 36 Boxes, More or Less, 
Labeled "Line Away Temporary Wrinkle Smoother, Coty," 415 F.2d 369 (3d Cir. 1969); United States v. Article 
of Drug .. . 47 Shipping Cartons, More or Less . .. "Helene Curtis Magic Secret," 331 F. Supp. 912 (D. Md. 
1971). 
79 Sudden Change, 409 F.2d at 742. The court did note, however, that if the manufacturer ceased any 
claims that the product temporarily affected the structure of the skin, the product would not be deemed a drug 
under the FDCA.Id. 
80 Line Away, 415 F.2d at 372. 
81 Magic Secret, 331 F. Supp. at 917. 
82 Coyne Beahm, Inc., 966 F. Supp at 1374. 
81 /d. at 1389. 
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indicate that intent must be proven by any particular kind of evidence."84 Further-
more, the district court noted that although no court had found intent without manu-
facturers' claims, "no court has held that intended use can be established solely by 
promotional representations."85 As a result, it held that FDA's reliance on the foresee-
able and actual use of the product to prove intent (in other words, that consumers 
would be expected to and do use nicotine for its effects on the body) was a reasonable 
interpretation of the FDCA and thus entitled to deference. 86 
Whether this ruling, if upheld on appeal,87 will impact FDA's regulation of cos-
metics is unclear. The mystique of the cosmetics industry relies heavily on advertis-
ing, so it is unlikely that manufacturers will cease to make claims about the efficacy of 
their products. If this holds true, Coyne Beahm may not have much effect on cosmet-
ics regulation, and things will continue as before. In the absence of such claims, how-
ever, and given the notoriety of AHAs, the court's ruling could open the door to stricter 
FDA regulation. 
There are signs that FDA may seek this kind of expansive definition of intent for 
cosmetics, one that would encompass the formulation of the product as evidence of its 
intended use. "If an active ingredient is present in a therapeutic concentration, the 
product is a drug, even if that product does not claim to produce the effect that will 
result from the action of the therapeutically effective ingredient," said John Bailey, 
Director of FDA's Office of Cosmetics and Colors, in 1996. "The presence of the 
ingredient, even if used in nontherapeutic amount[s], must be considered when deter-
mining its regulatory status. Therefore, the mere presence of the ingredient could 
make the product a drug regardless of the claims that are made on the label."88 For 
example, a product that includes the word "hormone" in its labeling or ingredient list 
will be deemed to convey an implied drug claim and will be regulated as a drug even 
if no other claims appear on the product's container.89 Thus, how FDA will regulate 
AHAs will depend, in part, on how the agency chooses to define "intent" in light of its 
regulatory goals with respect to cosmetics. 
III. How ARE AHAs LIKELY TO BE REGULATED UNDER CuRRENT 
INTERPRETATIONS OF THE FDCA? 
Whether FDA is likely to classify AHA as a cosmetic or as a drug depends on 
several factors. If the agency confines itself to the interpretation of the wrinkle cream 
cases, the decision will be the result of an individual analysis of the claims of each 
manufacturer. Those products with relatively benign claims will be classified as cos-
&4 /d. 
85 /d. at 1390. 
86 See Chevron v. Natural Resources Defense Council, 467 U.S. 837, 845 ( 1984)(when Congress has not 
spoken on an issue, reasonable interpretation of enforcing agency is entitled to deference). But see Action on 
Smoking and Health v. Harris, 655 F.2d 236, 240-41 (D.C. Cir. 1980) (noting that sufficient evidence of con-
sumer use requires a "substantial showing" and that courts have "accorded limited discretion to the Administra-
tion in its attempt to establish the requisite intent based primarily upon consumer use"). 
87 The district court's decision in Coyne Beam was appealed to the U.S. Court of Appeals for the Fourth 
Circuit. No opinion from the appellate court has been issued as of this writing, although news reports appearing 
after oral argument in the case have suggested that the three-judge panel was unconvinced by the government's 
arguments. See Saundra Torry, Duel in a Country Courthouse, With Tobacco Regulation at Stake, WASH. 
PosT, Aug. 18, 1997, at F7. 
88 Shaw, supra note 12, at 72. 
89 Cosmetic Products Containing Certain Hormone Ingredients; Notice of Proposed Rulemaking, 58 Fed. 
Reg. 47,611,47,612 (1993). 
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metics; those with more aggressive claims will be classified as drugs.90 In the past, any 
anti-aging claim made for a cosmetic product has caused the product to be regulated 
as a drug. Examples of such a claim, FDA has noted, include claims that the product 
"counteracts," "retards," or "controls" the aging process.91 Moreover, any claims that 
the_ product alters underlying layers of the skin or has more than a superficial effect 
would give FDA reason to characterize the product as a drug. 
Statements of FDA officials suggest that the agency is well aware of the inad-
equacy of cosmetics regulation to deal with products' enhanced effects.92 The agency's 
Center for Food Safety and Applied Nutrition (CFSAN) is hoping to develop a "regu-
latory strategy" over the next five to seven years for cosmetic products with pharma-
cological components and effects, a strategy that almost certainly will feature AHAs 
predominantly.93 But what type of regulation will result from this reconsideration is 
unclear. The agency could decide that AHA products with drug claims are unap-
proved new drugs that must be pulled from the market. On the other end of the cost 
spectrum is a reenactment of the 1987 scenario: FDA could send warning letters to 
overzealous AHA manufacturers, advising them to tone down their claims. 
If John Bailey's 1996 statements94 prove prophetic, FDA's move toward using the 
chemical composition of a product9s to determine its classification may augur consid-
erable regulation of AHAs. Evidence of such a trend appeared in 1993, for example, 
when FDA issued a notice of proposed rulemaking regarding hormones in cosmetic 
products. 96 Certain hormone ingredients had been marketed as OTC drugs for many 
years, and their safety at specific concentration levels had been established. Relying 
on this research, and desiring to keep hormones in cosmetics to levels that would "not 
have any therapeutic effects" or would "not affect the structure of any function of the 
body" (i.e., have no drug effect), FDA proposed that progesterone be permitted in 
cosmetics up to 5 mg/oz, and pregnenolone acetate in concentrations of0.5% or less.97 
Because insufficient information was available as to safe topical levels of estrogen, the 
9° For example, Neoteric Cosmetics' Alpha Hydrox AHA Facial Treatment, a widely available facial 
cream, contains the following claims on its box: "reduces the signs of aging," "[ s ]moothes surface imperfections 
caused by aging and sun damage," and "dramatically and rapidly improves surface texture, tone, firmness and 
elasticity of skin." FDA is likely to view an anti-aging claim as a drug claim (although this claim has been 
couched carefully in terms of the signs of aging rather than the aging process itself), but it seems likely that the 
other two claims include the word "surface" in order to avoid regulation as a drug. 
91 Food & Drug Admin., Import Alert No. 66-38 (Mar. 6, 1990). Examples of possible drug claims include 
claims that the product "rejuvenates," "repairs," or "restructures" the skin, or that the skin molecules would 
"absorb and expand" to erase wrinkles. I d. Note that because drugs are defined either as "intended for use in the 
... treatment or prevention of disease" or "intended to affect the structure or any function of the body," by 
characterizing as drugs products that claim only to control the "aging process," FDA implies that aging is a 
disease. The gender issues behind this characterization are too complex to be discussed here. 
92 John Bailey, Dir., Off. of Cosmetics & Colors, FDA, for example, has stated with respect to AHAs that 
the "legal scheme that applies to cosmetics ... is clearly inadequate when applied to products that have a 
physiological effect beyond that which occurs with traditional cosmetic products." F-D-C REP. ("The Rose Sheet"), 
Dec. II, 1995, at I, 3. Bailey's statement also may be interpreted as a call to Congress for amendment ofthe 
FDCA. 
93 F-D-C REP. ("The Rose Sheet"), Mar. II, 1996, at 5-6. 
94 See supra text accompanying note 88. 
9
' Significantly, in Aprill997 FDA recommended the toxicity of AHAs as a focus of study by the National 
Toxicology Program. See Announcement ofNominated Chemicals Approved and Under Consideration for Toxi-
cological Studies by the National Toxicology Program; Request for Comments, 62 Fed. Reg. 19,348 (1997). 
Not surprisingly, industry representatives have deemed such a study "unnecessary" and a "waste of scarce test-
ing resources." See Further Movement on Testing of AHAs, DRuG & CosM. INDUS., June I, 1997, at 6. 
96 See 58 Fed. Reg. at 47,611. No final rule has yet been issued. 
97 Jd. at 47,612. 
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agency proposed that any use of natural estrogen in cosmetic products would make 
those products unapproved new drugs.98 If this example serves as a model for AHA 
regulation, future product classifications would be dependent only on the products' 
formulation and not on any claims made as to their efficacy. 99 
Whether AHAs are determined to be a drug also is dependent on the political 
climate. FDA, like all administrative agencies, is engaged in a constant battle for self-
preservation. Thus, the agency must be at least somewhat responsive to Congress, 
which provides its funding and its statutory mandate. The Republican-controlled Con-
gress has expressed displeasure with the aggressive regulatory activities ofthe FDA, 100 
although whether displeasure will translate into amendment of the cosmetics provi-
sions of the FDCA remains to be seen. Coyne Beahm may serve as an important 
bellwether: If Congress ultimately determines that the courts have gone too far (public 
opinion serving as an important consideration), 101 it may seek to amend the defini-
tional portions of the FDCA to clarify or even to eliminate "intent." 
On the other hand, Congress eventually may decide that cosmetics are different 
from cigarettes in a way that supports more aggressive agency regulation. The first 
steps toward such a decision may have occurred in 1996, when several senators called 
for the enactment of a national uniformity law for cosmetic regulation. 102 More re-
cently, an attempt to preempt state regulation of cosmetics was thwarted by the efforts 
of Senator Edward Kennedy (D-MA), an outspoken critic of the industry, who has 
pointed to AHAs as a prime example of the potential dangers of unregulated cosmet-
ics. 103 Further debate on this issue should include a discussion of international harmo-
nization. 104 Because Japan and other countries recognize cosmeceuticals as a regula-
tory category, 105 effective regulation across national boundaries may require similar 
recognition in the United States. 
98 Id. 
99 See also United States v. Articles ofFood & Drug, 444 F. Supp. 266, 271 (E.D. Wis. 1978) (finding that 
"representation in the labeling or in the promotion of an article ... that it is or contains amygdalin, is a represen-
tation that the article is intended for use in the cure, mitigation, treatment and prevention of cancer in man" given 
publicity regarding such use). 
100 See, e.g., 142 CoNG. REc. S8612 (daily ed. Jul. 24, 1996)(statingthatFDA has been a "whipping boy" 
in recent times) (statement of Sen. Edward Kennedy (D-MA)); 142 CoNG. REc. Sll ,l29 (daily ed. Sept. 24, 
1996) ("I am as angry as I can be that the FDA is being given jurisdiction over tobacco.") (statement of Sen. 
Wendell Ford (D-KY)). One trade publication has stated that "since the Republican landslide victory in the 1994 
election [FDA] has been a mostly low profile organization, especially with regard to cosmetics." CosM. INsiDERS' 
REP., May 15, 1996. 
101 In other words, the public may respond strongly to any attempt to regulate personal habits. See, e.g., 
JoHN W. KINGDON, AGENDAS, ALTERNATIVES, AND PuBLIC POLICIES 146 (1984) (describing public outrage over, and 
subsequent abandonment of, seat belt interlocks requirement). 
102 See, e.g., 142 CoNG. REc. Sl2,053 (dailyed. Oct. 1, 1996)(statementofSen. Orrin G. Hatch (R-UT)); 
142 CoNG. REc. Sl2,020 (dailyed. Sept. 30, 1996)(statement of Sen. Judd Gregg (R-NH)). 
103 See, e.g., 143 CoNG. REc. S9148 (daily ed. Sept. 11, 1997) (statement of Sen. Kennedy) ("Alpha-
hydroxy acids have been linked to severe redness, burning, blistering, bleeding, rash, itching, and skin discolora-
tion. Most troubling, there is concern that alpha-hydroxy may promote skin cancer by increasing sensitivity to 
sun exposure. Yet these products are in the marketplace-with no warning labels and no limits on the concen-
trations that may be sold."). The preemption language was part of the Food and Drug Administration Modern-
ization and Accountability Act of 1997, S. 830, 105th Cong., 1st Sess. (1997), which was approved by the 
Senate on Sept. 24, 1997. A House vote is pending as of this writing. 
104 
"(T)here is a global trend of international harmonization for products such as cosmetics: The countries 
in the European Union, Latin America, and various Asian countries are working toward regulatory coopera-
tion." 142 CoNG. R.Ec. Sl2,020 (daily ed. Sept. 30, 1996)(statement of Sen. Gregg). 
IOl Bert J. Vermeer & Barbara A. Gilchrest, Cosmeceuticals: A Proposal for Rational Definition, Evalu-
ation, and Regulation, 132 ARCHIVES OF DERMATOLOGY 337,338-39 (1996). 
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Undoubtedly the industry's concerns about excessive agency regulation will be 
heard on Capitol Hill. On the other hand, "the perception that the government toler-
ates risks to the public might be more damaging than the risks themselves."106 FDA 
retains the option of informal regulatory efforts, including educating the public as to 
the safety of AHAs, 107 but the pace of scientific development calls for a more formal 
solution. 
IV. THE SHORTCOMINGS OF THE FDCA 
Given that the FDCA "is to be given a liberal construction consistent with the 
FDCA's overriding purpose to protect the public health,"108 and given the difficulty 
inherent in passing legislation, the optimal method of regulation is to work within the 
existing statutory framework. But, as the Commissioner of Food and Drugs noted 
before Congress in 1988, the science involved in the production of cosmetics - and 
the science involved in safety testing - has changed dramatically since the FDCA's 
enactment in 1938.109 It may be time for Congress to recognize this progress and 
amend the FDCA. 
A. The Inherent Flaws in the Intent Requirement 
FDA is charged with two responsibilities: to protect the public health and to 
protect the public economic well-being.110 The regulation of cosmetics therefore takes 
on two forms: ensuring the safety of cosmetic products and ensuring that consumer 
expectations are met. "Intended use"- as measured by advertising and labeling- is 
relevant only to the latter of these concerns in that consumer expectations are derived 
from the claims a manufacturer makes. In other words, whether a manufacturer ad-
vertises its product as "anti-aging" or merely "moisturizing," the product retains the 
same chemical composition and the same probability of harm. 111 A manufacturer will 
be wary of making specific claims because it seeks regulation of the product as a 
cosmetic and to avoid its regulation as a misbranded product. The result is likely to be 
increasingly vague claims that neither support a drug definition nor aid in defining 
consumer expectations. The industry is encouraged in this effort by the media, and 
particularly by women's magazines, which often feature articles on new cosmetic tech-
nology and are simultaneously beholden to the advertisers of those products. 112 A 
manufacturer no longer has to make any claim on its label beyond the fact that the 
108 Bacto-Unidisk, 394 U.S. at 798. 
109 Hearings, supra note 63, at 174-75 (statement of Dr. Frank E. Young, Comm'r. of Food and Drugs). 
110 See, e.g., Sudden Change, 409 F. 2d at 740 ("A primary purpose of the Act is the protection ofthe 
ultimate consumer's economic interests."); S. REP. No. 361, 74th Con g. ( 1935), reprinted in LEGISLATIVE REcoRD, 
supra note 38, at 239 (stating that the expansion of the definition of"drug" was necessary to protect the con-
sumer from products that are "worthless at best and some of which are distinctly dangerous to health"). 
111 As the Second Circuit noted in its wrinkle cream case, after holding the product to be a drug, 
It should be understood, however, that if the claimant ceases to employ these promotional claims and 
avoids any others which may fairly be interpreted as claiming to affect the structure of the skin in 
some physiological, though temporary, way, then assuming arguendo that no actual physical effect 
exists, the product will not be deemed a drug for purposes of the Act. 
Sudden Change, 409 F.2d at 742. It is unclear what the court's decision would have been in this scenario if an 
actual physical effect did exist. 
112 See, e.g., NAOMI WOLF, THE BEAUTY Mvrn70(1991) ("Women are deeply affected by what their maga-
zines tell them (or what they believe they tell them) because they are all most women have as a window on their 
own mass sensibility."). 
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product contains AHAs - the consumer likely will recognize the significance. 
Furthermore, a literal interpretation of the intent requirement (one that does not 
rely on the chemical composition of the product) would result in classifying virtually 
all cosmetics as drugs because almost every cosmetic can be said to contain a claim 
that the product wi 11 affect the structure of the body. 113 Moisturizers, long considered a 
cosmetic product, soften and smooth the top layers of the skin. Hair conditioners 
temporarily coat and smooth the cuticles of the hair shaft. To apply the broad interpre-
tation of "drug" not only "render[s] meaningless the distinction made by Congress 
between drugs and cosmetics"114 but also gives the agency a seemingly boundless 
amount of discretion. FDA can pick and choose among cosmetics on the market, 
interpreting some claims as drug claims and others as cosmetic claims. 
Finally, the statute's reliance on "intended use" provides no clear connection to 
product safety. Of course, other controls exist to provide this protection: an adulter-
ated cosmetic can be removed from the market, and potential product liability suits 
operate as somewhat effective constraints on unsafe cosmetics. But both ofthese methods 
require a substantial amount of time to accumulate sufficient adverse reactions to seek 
action, time during which increasing numbers of consumers are being harmed. 115 Al-
though an FDA regulation requires that cosmetics that have not been tested adequately 
for safety carry a warning to that effect, 116 the fact that submission of information to 
the agency is completely voluntary hampers FDA's efforts to enforce the regulation. 117 
One question FDA should consider, then, is whether the primary gap between cos-
metic regulation and drug regulation - the premarket review - is warranted in the 
field of cosmetics. On the one hand, premarket testing would prevent potentially harmful 
cosmetic products from ever reaching the market. On the other hand, the number of 
cosmetics found to be dangerous enough to pull from the market has been relatively 
small. 118 In addition, the high expenditures and time delays that premarket testing 
requires may force many products and small businesses from the market, especially 
given the short lifespan of many cosmetic products. 119 Moreover, because cosmetics 
are a luxury item, customers can take the time to find the product that works best for 
them and often develop a loyalty toward a particular line. Industry thus has an incen-
tive to create good word-of-mouth by ensuring the efficacy and safety of its products. 
mAs Judge Mansfield noted in dissent in Sudden Change, "[l]fthe claim that a product will alter the 
appearance of the body ... requires that the product be classified as a drug, practically all cosmetics (and indeed 
articles such as girdles and brassieres) would be required to be so classified." 409 F.2d at 744 (Mansfield, J., 
dissenting). See also Naomi M. Kanof, Cosmetics: Proposal for Redefinition, I J. AMER. AcAD. DERMATOLOGY 
67 (1979) (noting that it is not possible to "cleanse, beautify, promote the attractiveness or alter the appearance 
of the skin" without affecting the structure and function of the body). 
114 Sudden Change, 409 F. Supp. at 744 (Mansfield, J., dissenting). 
115 
"Manufacturers do not have to determine the safety of their products before selling them or tell the Food 
and Drug Administration what products they are selling and what ingredients are used in them. Many manufac-
turers have not voluntarily given such information to the agency. As a result, a hazardous cosmetic can be 
marketed until the Food and Drug Administration obtains information to prove that the product may be injurious 
to users." Report to the Congress of the United States by the Comptroller General, Lack of Authority Hampers 
Attempts to Increase Cosmetic Safety (HRD 78-139) (Aug. 8, 1978), reprinted in Hearings, supra note 63, at 
605. 
116 21 C.F.R. § 740.10. 
117 U.S. GEN. Accr. OFF., LACK OF AtrrHORITY HAMPERS ATTEMPTS ro INCREASE CosMETIC SAFETY (1978), 
reprinted in HuTT & MERRILL, supra note 42, at 820. 
118 See, e.g., Greff, supra note 62, at 243 ("This scheme works because cosmetics are by nature generally 
low risk and because of industry self-regulation."). 
119 See S.L. Mayham, Chemicals in Cosmetics, 7 Fooo DRUG CosM. L.J. 184, 190-91 (1952)(decrying the 
effect increased cosmetic regulation would have on small businesses). 
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But companies also must remain competitive. If its competitors are jumping on the 
AHA bandwagon, a company must introduce its own product, preferably one at a 
higher concentration than those already on the market. Premarket testing would pre-
empt the escalation wars by setting a safety level above which products would not be 
allowed on the market. 
B. Proposals for Reform 
The advances that have been made in cosmetic technology, and the gradual blur-
ring of the line between cosmetics and drugs, cannot be ignored. Cosmetic manufac-
turers are hesitant to incorporate new technology that might be helpful to acne suffer-
ers, for example, or to make direct claims regarding the efficacy of their products for 
fear that the products will be regulated as new drugs. 12° FDA, for its part, must be 
concerned about resource allocation as well as consumer safety. Although the agency 
may be tempted to classify borderline products as drugs to place the burden of proof 
with respect to· safety on the manufacturer, such a decision commits considerable 
resources to review of new drug applications. 
It is clear that what have become known as "cosmeceuticals"- cosmetic prod-
ucts with drug-like effects - have existed for years. FDA refuses to recognize 
"cosmeceutical" as a valid term, 121 most likely because the term does not appear in the 
FDCA, despite the fact that the industry has long used the term to describe products 
that seek to cure rather than merely to camouflage an appearance problem.122 Because 
cosmetic technology is likely to advance, FDA, along with Congress, must decide 
whether, and how, to regulate these products as a unique category. 
FDA may, of course, continue to disclaim the existence of a separate cosmeceutical 
category and to regulate these products under the current scheme, thus allowing manu-
facturers to avoid drug regulations by promoting their products with vague claims. 
Whether cosmetics (that is, cosmeceuticals for which nontherapeutic claims were made) 
would undergo premarket testing is a decision that would remain for the manufac-
turer. Although the FDCA neither requires premarket testing of cosmetics nor prohib-
its the use of most ingredients, FDA "strongly urges cosmetic manufacturers to con-
duct whatever toxicological or other tests are appropriate to substantiate the safety of 
their cosmetics."123 Many cosmetic manufacturers do, in fact, conduct premarket tests 
on their products to avoid product liability suits and the loss of goodwill associated 
with an ineffective or harmful product.124 
Dr. John Bailey, Director of FDA's Office of Cosmetics and Colors, has suggested 
that one solution to the cosmeceutical debate would be the creation of a premarket 
industry review system, working in parallel to the Cosmetic Ingredient Review (CIR).125 
The CIR is an industry review panel established in 1976 by the CTFA to review the 
120 See, e.g. , Venneer & Gilchrest, supra note 105, at 338. 
121 
"Cosmeceutical," CFSAN, FDA, Office of Cosmetics Fact Sheet (Feb. 3, 1995). 
122 See, e.g., Cosmeceuticals: New Class of Products Offers Important Benefits for Aging Customers, 
CHAIN DRuG REv., Sept. 23 1996, at 92. 
123 COSMETICS HANDBOOK, supra note 45. 
124 
"The law says it is prohibited for a company to produce a cosmetic product that could be injurious to the 
consumer under nonnal use .... lfl am a cosmetic official, and I have that as a law, why do I need some kind of 
review by anybody prior to marketing? ... If you can't have happy, healthy consumers, you are going to lose a 
lot of money." Cosmeceuticals, supra note 122, at 92 (quoting Gerald McEwen, Vice Pres. for Sci., CTFA). 
Ill Joanna Ramey, Review Board Could Give Nod to Alpha-Hydroxies by June, WoMEN's WEAR DAILY 
(WWD), Mar. I, 1996, at 26. Bailey is a nonvoting member of the CIR./d. 
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safety of cosmetic ingredients and to make the results of those reviews public. While 
this would be appropriate for many cosmetic products, it would not be appropriate for 
products such as AHAs. Self-regulation becomes more tenuous the greater the risk of 
harm; the FDCA's premarket regulation of drug manufacturers reflects a judgment 
that the societal costs of a harmful product are greater than the costs borne by the 
company through litigation. In addition, the trend toward confidential settlements 
may hamper the efficacy of the tort system in regulating product safety. Because the 
argument for drug regulation holds true for cosmeceuticals, which have a greater 
likelihood of causing harm than cosmetics, some form of regulation is desirable. 
If cosmeceuticals are to be given special consideration, the FDCA must be amended 
to reflect recognition of their existence. Congress could err on the stronger end of the 
regulatory spectrum by requiring that all cosmeceuticals be regulated as drugs no 
matter what claim is made for them. In other words, the presence of an active ingredi-
ent would be deemed sufficient proof of intended use as a drug. While this would 
address safety concerns, it also likely would result in inordinately high resource ex-
penditures, because proof of efficacy would be required even for those products about 
which relatively benign claims were made. If a product claims only to improve the 
appearance, the customer is in as good a position, if not better, to judge whether that 
claim has been satisfied. Contrary to drug claims, there is no concern that a customer 
will rely on the unsubstantiated claims of a cosmetic product and thus fail to seek 
treatment for a condition - in other words, the claims themselves present no signifi-
cant health issues. 
Alternatively, Congress could err on the weaker end of the spectrum by amending 
section 32l(g)(l) oftitle 21 of the United States Code to exempt cosmetics as well as 
food from the definition of "drug." By making the definitions of "drug" and "cos-
metic" mutually exclusive, the amended FDCA would end the current confusion over 
products that seem to straddle the line, as products intended for "cleansing, beautify-
ing, promoting attractiveness, or altering the appearance"126 would be considered cos-
metics exclusively. This proposal would please the industry as well as those concerned 
with the regulatory reach of FDA and would place greater regulatory responsibility 
on the market and publicity outlets. Such an amendment does not, however, address 
the very problem to which cosmeceuticals give rise: the potential harmful effects of 
active ingredients in cosmetics. The amendment also lends itself to abuse, as manu-
facturers may clothe true drugs as cosmetics by making claims only as to superficial 
effects. These dangers could be avoided in part by strengthening the current frame-
work for cosmetic regulation to require some form of premarket testing, but this would 
result in an ineffective use of resources because these regulations would encompass all 
cosmetic products, including those already generally recognized as safe. 127 
The optimal method of regulation lies between these two, in the creation of a new 
category of regulation for cosmeceuticals that would include AHAs. Cosmeceuticals 
would be defined as those products containing an active ingredient128 for which cos-
126 21 U.S.C. § 32l(i) (FDCA § 20l(i)). 
127 Of course, an exception could be made for these products; this would result in much the same system 
proposed below. 
128 A reliance on active ingredients as the determining factor for classification as a cosmeceutical may itself 
require revision of FDA's regulations. For example, 21 C.F.R. § 60.3(b )(2) defines "active ingredient" as "any 
component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, miti-
gation, treatment, or prevention of disease, or to affect the structure or any function of the body of man or of 
animals." Because of the difficulties inherent in the current interpretations of"intent," see supra part IV.A, 
"intended to" should be read here to mean "known to or believed to." De minimis effects on the body should be 
deemed irrelevant to the classification. 
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metic claims are made; the focus of their premarket regulation would thus be on safety 
rather than on efficacy. Using its composition to classify the product would direct 
FDA's attention to safety concerns, and the requirement of cosmetic claims would 
properly leave the protection of consumer expectations to the market and FDA's regu-
latory power over adulterated and misbranded cosmetics. 
A focus on the active ingredients of a product, and thus on the likely effects of 
that product, recognizes the heightened potency of cosmeceuticals. The Director of 
FDA's Office of Cosmetics and Colors has been an outspoken proponent of an effects 
test. He noted in a 1994 speech, 
In the final analysis, it is well established that AHAs exert an effect on the 
skin .... If, under the prescribed conditions of use, the effect of the formula-
tion is only superficial, then FDA would not consider the effect to be a drug 
effect .... If, under prescribed conditions of use, the effect is more than 
superficial . . . , I believe that these products are functioning as drugs and 
should be regulated as such. 129 
In addition, the creation of a cosmeceutical category would frustrate manufacturers' 
attempts to escape premarket regulation by promoting the product with vague, un-
provable claims. Once a company decision has been made to reap the market benefits 
of an active ingredient, the manufacturer must bear the costs of that decision. 130 
Several different options exist for the regulation of the safety of cosmeceuticals, 
all of which build on the industry's already-existing incentive to conduct premarket 
product testing. The amended statute could require companies to submit proof that a 
certain level of testing had been conducted but require less extensive information than 
is currently required for new drugs. Alternatively, it could establish a system similar 
to that now existing for dietary supplements.131 Under the FDCA, dietary supplement 
labels are permitted to claim a benefit related to a nutrient-deficiency disease as long 
as the manufacturer has proof that the statement is truthful and not misleading and 
the label contains a statement noting that the label has not been evaluated by FDA and 
that the product is "not intended to diagnose, treat, cure, or prevent any disease."132 
Similarly, cosmeceuticals could be permitted to contain active ingredients as long as 
the label carried a statement noting that FDA had not approved the safety of the 
ingredient and that the product was not intended to reverse the aging process. An-
other alternative would be to accept tests conducted by the CIR as sufficient proof, 
which would encourage the industry to combine its resources. And finally, the scheme 
could direct FDA to establish monographs similar to those existing for drugs that 
would establish permissible levels of active ingredients in cosmetics. 
The optimal choice among these or additional options is best left to the political 
process - to discussions among the agency, the industry, the public, and Congress -
as well as to discussions within the scientific community. Whatever the decision, it 
129 Greff, supra note 62, at 257 (quoting John E. Bailey, Jr., Ph.D., then Acting Dir., Off. of Cosmetics & 
Colors, FDA, Skin Care-State of the Art: A Regulatory View-Alpha-Hydroxy Acid, Speech at the Annual 
Spring Seminar of the New York Chapter of the Society of Cosmetic Chemists, New York, NY (Apr. 6, 1994 )). 
130 Of course, the consumer ultimately will bear these costs; whether or not he or she decides to buy the 
product, and therefore absorb these costs, will depend on what value the consumer places on safety. 
131 Attorney William Pendergast has advocated this option. See, e.g., David C. Steinberg, Cosmeceuticals: 
An Advanced Forum for Manufacturers, CosMS. & ToiLETRIES, Jun. I, 1996, at 43; F-D-C REP. ("The Rose 
Sheet"), Mar. 18, 1996, at 9. 
132 See 21 U.S.C. §§ 32I(g)(l), 343(r)(6) (FDCA.§§ 201(g)(l), 403(r)(6)). 
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seems clear that many cosmetics can no longer be regarded as without risk. 133 As the 
demand for more effective treatments increases, so will the level of active ingredients 
in cosmetics and the level of regulation needed to ensure the public's safety. 
V. CONCLUSION 
After FDA's crackdown on anti-aging creams in 1987, the New York Times noted 
that cosmetic manufacturers either had to prove drug-like claims or abandon the 
pseudoscientific advertising. "But that's not so terrible an imposition," it continued. 
"All the FDA is asking is that fantasy and reality be kept separate. The cosmetic 
companies need only retreat back to fantasy, and their customers will live happily as 
before."134 This may have been an adequate response at the time, but it seems some-
what cavalier today, when cosmetics are encroaching further and further into the realm 
of drugs. As the Supreme Court noted in 1943, 
The purposes of [the FDCA] thus touch phases of the lives and health of 
people which, in the circumstances of modem industrialism, are largely be-
yond self-protection. Regard for these purposes should infuse construction of 
the legislation if it is to be treated as a working instrument of government 
and not merely as a collection of English words. 135 
Society as a whole, we should remember, shares the cost of inadequate safety, as 
well the costs of more psychic harms. FDA's decision on how AHAs should be regu-
lated will serve as an initial point of discussion, not only on the government's role in 
regulating potentially harmful products, but also on the lengths we are willing to go to 
preserve a youthful look. 
133 
"Specifically, in 1938, cosmetics were differentiated from the agency's authority in food and drugs, and 
later devices, because it was judged and has continued to be judged by Congress that though these products are 
important, they did not quite present the risk that the other products do." Hearings, supra note 63, at 52 (state-
ment of Dr. Frank E. Young, Comm'r of Food and Drugs). 
134 GERALD McKNIGHT, THE SKIN GAME: THE INTERNATIONAL BEAUTY BusiNEss BRUTALLY EXPOSED 185 ( 1989). 
135 United States v. Dotterweich, 320 U.S. 277,280 (1943). 
